Type I interferon pathway activation in connective tissue disease associated interstitial lung disease - Top-Institutions - MDSpire

Type I interferon pathway activation in connective tissue disease associated interstitial lung disease

  • By

  • Tobias M. Defesche

  • Thomas Koudstaal

  • Marjan A. Versnel

  • Odilia B.J. Corneth

  • Zana Brkic

  • June 11, 2026

  • 0 min

Share

Top Institutions in Pulmonary

Brief introduction explaining scope and methodology.

  • #1

    University of Pittsburgh Medical Center
    University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

    Key Differentiators

    • Pulmonology

  • #2

    The Johns Hopkins Hospital
    The Johns Hopkins Hospital

    Baltimore, Maryland

    Key Differentiators

    • Pulmonology

  • #3

    Shanghai Pulmonary Hospital
    Shanghai Pulmonary Hospital

    Shanghai, China

    Key Differentiators

    • Pulmonology

  • #4

    Tongji University School of Medicine
    Tongji University School of Medicine

    Shanghai, China

    Key Differentiators

    • Pulmonology

  • #5

    Temple University
    Temple University

    Philadelphia, Pennsylvania

    Key Differentiators

    • Pulmonology

Original Source(s)

Type I interferon pathway activation in connective tissue disease associated interstitial lung disease

  • by Tobias M. Defesche, Thomas Koudstaal, Marjan A. Versnel, Odilia B.J. Corneth, Zana Brkic

  • June 11, 2026

Related Content

Optimizing Treatment for CTD-ILD

When autoimmune or connective tissue diseases cause inflammation or scarring of the lungs, both diagnosis and effective management can be challenging.

  • August 8, 2023

  • 5 min
Botulinum Toxin Evaluated in Digital Ischemia

Individual-level meta-analysis examines response, dosing, and safety across ischemic etiologies

7 Days Noninferior in Bacteremia

BALANCE compared 7 vs 14 days of treatment among hospitalized patients with bloodstream infections.